28.06.2021 Vivoryon Therapeutics N.V.  NL00150002Q7

DGAP-News: Vivoryon Therapeutics N.V.: Ordinary General Meeting of Shareholders of Vivoryon Therapeutics N.V.


 

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): AGM/EGM
Vivoryon Therapeutics N.V.: Ordinary General Meeting of Shareholders of Vivoryon Therapeutics N.V.

28.06.2021 / 18:00
The issuer is solely responsible for the content of this announcement.


 

Ordinary General Meeting of Shareholders of Vivoryon Therapeutics N.V.

 

HALLE (SAALE) / MUNICH, GERMANY, June 28, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines today announced, that its shareholders approved all resolutions proposed by the Company's Board of Directors at the Company's Annual General Meeting which took place on Monday, June 28, 2021, as a virtual event, including the:

  • Advisory vote on the remuneration report.
  • Adoption of the 2020 annual accounts.
  • Release from liability of the company's executive directors.
  • Release from liability of the company's non-executive directors.
  • Adoption of the remuneration policy.
  • Re-appointment of Dr. Michael Schaeffer as executive member of the Board.
  • The Board nominated Dr. Michael Schaeffer for reappointment as executive member of the Board and regranted him the title of Chief Business Officer, effective October 1st, 2021.
  • Adoption of the long term incentive plan.
  • Amendments to the company's articles of association.
  • Re-appointment of KPMG Accountants N.V., The Netherlands,as external auditor for the financial year 2021.
  • Authorization to acquire own shares.


47.37 % of the voting shares were represented at the 2021 Vivoryon Therapeutics N.V. AGM.


All resolutions proposed by the Company's Board of Directors were approved at the meeting with a large majority. The voting results can be found on the Company's website:
www.vivoryon.com/investors-news/ordinary-general-meeting-of-shareholders-2021

 

Dr. Ulrich Dauer, Chief Executive Officer of Vivoryon Therapeutics N.V, said: "We would like to take this opportunity to thank all of our employees, advisors and consultants, as well as the members of the non-executive Board, partners and shareholders for their commitment, trust and support."
 

###


For more information, please contact:

Vivoryon Therapeutics N.V.
Investor Contact

Dr. Manuela Bader, Director IR & Communication
Tel: +49 (0)345 555 99 30
Email: [email protected]


Media Contact
Trophic Communications

Gretchen Schweitzer / Valeria Fisher
Tel: +49 (0)172 861 8540 or +49 (0)175 8041816
Email: [email protected]

About Vivoryon Therapeutics N.V.

Vivoryon is a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation we strive to change the live of medically underserved patients suffering from severe diseases. We leverage our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings before they cause irreversible damage. Beyond our lead program, varoglutamstat, which is in Phase2 clinical development to treat Alzheimer's disease, we have established a solid pipeline of orally available small molecule inhibitors for various indications including cancer, inflammatory diseases and fibrosis.

www.vivoryon.com

Forward Looking Statements

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics N.V. as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.



28.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Vivoryon Therapeutics N.V.
Weinbergweg 22
06120 Halle/Saale
Germany
Phone: +49 (0)345 555 9900
Fax: +49 (0)345 555 9901
E-mail: [email protected]
Internet: www.vivoryon.com
ISIN: NL00150002Q7
WKN: A2QJV6
Listed: Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; Amsterdam
EQS News ID: 1212882

 
End of News DGAP News Service

1212882  28.06.2021 

fncls.ssp?fn=show_t_gif&application_id=1212882&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 0,00 0,00 0,00 0,00 0,00 10,76 0,00
EBITDA1,2 -13,67 -9,86 -7,68 -7,63 -15,87 -12,63 0,00
EBITDA-Marge3 0,00 0,00 0,00 0,00 0,00 -117,38 0,00
EBIT1,4 -13,77 -9,96 -7,70 -7,72 -16,01 -12,79 0,00
EBIT-Marge5 0,00 0,00 0,00 0,00 0,00 -118,87 0,00
Jahresüberschuss1 -13,89 -8,01 -7,74 -7,82 -16,51 -12,66 0,00
Netto-Marge6 0,00 0,00 0,00 0,00 0,00 -117,66 0,00
Cashflow1,7 -13,26 -12,12 -6,99 -11,61 -14,01 -11,26 0,00
Ergebnis je Aktie8 -1,82 -0,98 -0,94 -0,62 -0,83 -0,63 -0,51
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: KPMG

INVESTOR-INFORMATIONEN
©boersengefluester.de
Vivoryon Therapeutics
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A2QJV6 14,600 351,94
KGV 2024e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,00 -13,24
KBV KCV KUV EV/EBITDA
21,26 - 32,70 -26,84
Dividende '22 in € Dividende '23e in € Div.-Rendite '22e
in %
Hauptversammlung
0,00 0,00 0,00 22.06.2022
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
15.06.2022 30.09.2022 22.11.2022 28.04.2022
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
24,69% 58,73% 41,20% 18,89%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Vivoryon Therapeutics N.V.  ISIN: NL00150002Q7 können Sie bei EQS abrufen


Biotechnologie , A2QJV6 , 05Y , XETR:PB9